Relationships between interleukin-12B and interleukin-10 gene polymorphisms and hepatitis C in Chinese Han hemodialysis patients

Figures & data

Table 1. Sequences of PCR amplifying primers.

Gene	PCR amplifying primers	Annealing temperature(°C)
IL10–592	forward 5′-CCTAGGTCACAGTGACGTGG-3′	57
C/A	reverse 5′- GGTGAGCACTACCTGACTAGC-3′
IL10–819	forward 5′-TGCTGGAGATGGTGTACA-3′	57
C/T	reverse5′-TAGTGAGCAAACTGAGGCACAGAAAT-3′
IL12B-1188	forward 5′-GATATCTTTGCTGTATTTGTATAGTT-3′	52
3′ UTR C/A	reverse 5′- AATATTTAAATAGCATGAAGGC-3′

Notes: IL, interleukin; PCR, polymerase chain reaction; TNF, tumor necrosis factor.

Table 2. Comparison of clinical features between anti-HCV(+) and anti-HCV(−) groups.

	Anti-HCV (+) (179)	Anti-HCV (−) (705)	p^a Value
Gender (%)
Male	122 (68.2%)	434 (61.6%)	>0.05^b
Female	57 (31.8%)	271 (38.4%)
Blood transfusion
Yes	114 (63.7%)	311 (44.1%)	<0.001^b
No	65 (36.3%)	394 (55.9%)
Kidney transplantation
Yes	9 (5.0%)	11 (1.6%)	<0.01^b
No	170 (95.0%)	694 (98.4%)
Dialyzer reuse
Yes	70 (39.1%)	55 (7.8%)	<0.001^b
No	109 (60.9%)	650 (92.2)

Note: ^at-test; ^bX²-test.

Table 3. Demographic and clinical features of the persistent, viral clearance and anti-HCV (−) groups.

	Anti-HCV (+) (n = 179)
Characteristics	Persistent infection (n = 143)	Viral clearance (n = 36)	P^1	Anti-HCV (−) (n = 705)	P^2	P
Age (mean ± SD)	52.71 ± 11.75	55.44 ± 11.08		52.46 ± 13.86		>0.05
Gender, n (%)
Male	99 (69.2%)	23 (63.9%)		434 (61.6%)		>0.05
Female	44 (30.8%)	13 (36.1%)		271 (38.4%)
ALT (U/L)	27.58 ± 32.23	11.14 ± 7.14	<0.001	11.74 ± 12.30	<0.001	<0.001
≥40	30 (21.0%)	1 (2.7%)		15 (2.1%)		<0.001
<40	113 (79.0%)	35 (97.3%)		690 (97.9%)
AST (U/L)	25.42 ± 21.32	14.97 ± 7.86	=0.001	16.36 ± 14.93	<0.001	<0.001
≥40	18 (12.6%)	2 (5.5%)		37 (5.2%)		<0.01
<40	125 (87.4%)	34 (94.5%)		668 (94.8%)
GGT (U/L)	50.10 ± 44.32	26.66 ± 18.75	=0.001	29.64 ± 35.99	<0.001	<0.001
≥50	48 (33.6%)	5 (13.9%)		98 (13.9%)		<0.001
<50	95 (66.4%)	31 (86.1%)		607 (86.1%)

Notes: P¹: Persistent infection group versus viral clearance group, P²: Persistent infection group versus Anti-HCV (−) group.

P: Persistent infection group, viral clearance group and anti-HCV (−) group.

ALT, alanine aminotransferase; AST, aspartate aminotransferase; GGT, γ-glutamyltransferase.

Table 4. Comparison of frequencies of genotypes and alleles between the hepatitis C virus (HCV) infection and HCV non-infection groups.

	Anti-HCV (+)	Anti-HCV (−)
Genes	179 (20.2%)	705 (79.8%)	p^a Value	OR^a (95% CI)
IL-12B
AA	92 (51.4%)	113 (16.1%)	–	1.00 (reference)
CC	45 (25.1%)	276 (39.1%)	<0.001	0.23 (0.15–0.37)
CA	42 (23.5%)	316 (44.8%)	<0.001	0.19 (0.12–0.30)
CC + CA	87 (48.6%)	592 (83.9%)	<0.001	0.21 (0.14–0.31)
A	226 (63.1%)	542 (38.4%)	–	1.00 (reference)
C	132 (36.9%)	868 (61.6%)	<0.001	0.40 (0.31–0.52)
IL-10-592
CC	25 (14.0%)	89 (12.6%)	–	1.00 (reference)
CA	80 (44.7%)	348 (49.4%)	0.520	0.69 (0.22–2.13)
AA	74 (41.3%)	268 (38.0%)	0.549	1.41 (0.46–4.38)
IL-10-819
CC	25 (14.0%)	89 (12.6%)	–	1.00 (reference)
CT	79 (44.1%)	350 (49.6%)	0.177	0.47 (0.16–1.41)
TT	75 (41.9%)	266 (37.7%)	0.993	0.99 (0.33–2.99)

Note: ^aLogistic regression model, adjusted by age, gender, duration of hemodialysis, blood transfusion history, kidney transplantation and dialyzer reuse.

Table 5. Comparison of frequencies of genotypes between the hepatitis C virus (HCV) persistent infection and HCV clearance groups.

Genes	Persistent infection 143 (79.9%)	Viral clearance 36 (20.1%)	p^a Value	OR^a (95% CI)
IL-12B
AA	77 (53.8%)	15 (41.7%)	–	1.00 (reference)
CC	35 (24.5%)	10 (27.8%)	0.44	0.70 (0.28–1.75)
CA	31 (21.7%)	11 (30.5%)	0.14	0.50 (0.20–1.27)
CC + CA	66 (46.2%)	21 (58.3%)	0.19	0.60 (0.28–1.29)
A	185 (64.7%)	41 (56.9%)	–	1.00 (reference)
C	101 (35.3%)	31 (43.1%)	0.26	0.73 (0.43–1.26)
IL-10-592
CC	21 (14.7%)	4 (11.1%)	–	1.00 (reference)
CA	66 (46.2%)	14 (38.9%)	0.808	0.86 (0.25–2.92)
AA	56 (39.2%)	18 (50.0%)	0.366	0.57 (0.17–1.92)
IL-10-819
CC	20 (14.0%)	5 (13.9%)	–	1.00 (reference)
CT	65 (45.5%)	14 (38.9%)	0.847	1.12 (0.36–3.52)
TT	58 (40.6%)	17 (47.2%)	0.084	0.82 (0.26–2.54)

Note: ^aLogistic regression model, adjusted by age, gender.